---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-054483"
form_type: "8-K"
ticker: "TMCI"
cik: "0001630627"
company_name: "TREACE MEDICAL CONCEPTS, INC."
filed_at: "2021-11-04T23:59:59+00:00"
generated_at: "2026-06-28T13:03:16.364588+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Treace Medical Q3 revenue $21.6M (+52% YoY); net loss ($6.4M); FY21 guidance reaffirmed $90-95M

## Summary
- Revenue $21.6M, up 52% YoY from $14.3M; gross margin 80.4% (+80 bps).
- Net loss ($6.4M) or ($0.12) per share vs ($2.8M) or ($0.08) in Q3 2020.
- Full-year 2021 revenue guidance reaffirmed at $90M-$95M (57-65% growth).
- Cash $109.5M; launched Adductoplasty System; appointed two new board members.
- ALIGN3D study showed 0.9% recurrence at 12 months; first Mini3D patient treated.

## SEC filing metadata
- accession: 0001564590-21-054483
- form_type: 8-K
- ticker: TMCI
- cik: 0001630627
- company_name: TREACE MEDICAL CONCEPTS, INC.
- filed_at: 2021-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1630627/000156459021054483/0001564590-21-054483-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1630627/000156459021054483/tmci-8k_20211104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-054483
- JSON: https://secwatch.observer/filing/0001564590-21-054483.json
- Plain text: https://secwatch.observer/filing/0001564590-21-054483.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.